GlassScriptPhysician profile
Moshe Ornstein
NPI 1043509862
$248,968.81
in general payments reported to CMS, 2019-2025
20 companies · $21K in 2025
The $21K reported for 2025 was more than what 88% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $14K · 2021: $43K · 2022: $61K · 2023: $46K · 2024: $33K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $48K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Travel and Lodging: $6,359 · Honoraria: $1,980 · Food and Beverage: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $48,469.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,113.00 |
| Travel and Lodging | $6,358.90 |
| Honoraria | $1,980.00 |
| Food and Beverage | $1,644.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $77,458.77 | 2019-2024 | |
| Eisai INC. | $56,624.30 | 2020-2025 | |
| Pfizer INC. | $40,451.32 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $33,227.01 | 2020-2024 | Keytruda |
| Exelixis INC. | $29,258.62 | 2019-2025 | Cabometyx |
| Seagen INC. | $7,470.00 | 2023 | Padcev |
| Pfizer International LLC | $2,520.00 | 2020 | |
| Aveo Pharmaceuticals, INC. | $900.00 | 2022 | |
| Celgene Corporation | $900.00 | 2022 | |
| Janssen Biotech, INC. | $99.99 | 2021 | |
| Telix Pharmaceuticals | $21.00 | 2024 | Illuccix |
| Dendreon Pharmaceuticals LLC | $19.10 | 2022 | |
| Amgen INC. | $18.70 | 2023 | Blincyto |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moshe Ornstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.